Novartis Ag (NVSEF) Long-Term Deferred Tax (2009 - 2026)

Novartis Ag has disclosed Long-Term Deferred Tax across 12 years of filings, most recently posting $600.0 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $600.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $600.0 million (changed N/A YoY), and the FY2025 annual result was $5.4 billion, up 1069.46% from the prior year.
• Long-Term Deferred Tax came in at $600.0 million for Q1 2026 at Novartis Ag, down from $5.4 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $5.4 billion in Q4 2025 to a low of $34.0 million in Q4 2023.
• The 5-year median for Long-Term Deferred Tax is $600.0 million (2026), against an average of $1.9 billion.
• Peak annual rise in Long-Term Deferred Tax reached 7528.3% in 2023, while the deepest fall reached 99.09% in 2023.
• Novartis Ag's Long-Term Deferred Tax stood at $3.7 billion in 2022, then sank by 99.09% to $34.0 million in 2023, then surged by 1267.65% to $465.0 million in 2024, then soared by 1069.46% to $5.4 billion in 2025, then sank by 88.97% to $600.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $600.0 million (Q1 2026), $5.4 billion (Q4 2025), and $5.2 billion (Q2 2025), per Business Quant data.